INACTIVATION OF HIV

通过输注细胞传播病原体 而从血液中提取的蛋白质产品是一个持续和严重的 有问题。拟议的研究旨在评估这两项研究 病毒灭活的物理和化学方法 在这些产品中。最初将在以下位置选择加工方法 易于量化的灭菌效果基础 病毒，以及恢复完整和功能正常的红细胞， 血小板和血浆凝血因子。在许诺之后 已经确定了方法，它们在灭活方面的效率 艾滋病毒和B型以及非甲非乙型肝炎病毒 分别在组织培养和黑猩猩身上进行评估。 最后，展示了大量病毒灭菌的新鲜冰冻血浆， 冷沉淀物，红细胞和血小板单位 浓缩剂将在临床上进行制备和评估。 纽约血液中心特别适合 实现这些目标是因为其广泛的研究与 血液传播病毒及其开发和评价的经验 适用于纯化蛋白的病毒灭活方法 衍生品，而且由于我们灵长类设施的可用性 在利比里亚。这个项目将进一步受益于我们提供的 资源材料；我们的实验室、中试工厂和组件 设施；以及我们处理和分析血浆的经验 蛋白质和血液成分，并在制备实验和 获得许可的生物制品，用于治疗人类。

The transmission of pathogenic agents by transfusion of cellular and protein products derived from blood is an ongoing and serious problem. The proposed studies are designed to evaluate both physical and chemical approaches for the inactivation of viruses in these products. Process methods will be selected initially on the basis of sterilization efficacy against easily quantifiable viruses, and of recovery of intact and functioning red cells, platelets, and plasma coagulation factors. After promising approaches have been identified, their efficiency in inactivating HIV and type B and non-A, non-B hepatitis viruses will be evaluated in tissue culture and in chimpanzees, respectively. Finally, demonstration lots of virus sterilized fresh frozen plasma, cryoprecipitate, and units of red blood cell and platelet concentrates will be prepared and evaluated clinically. The New York Blood Center is especially well suited to accomplish these goals because of its extensive research with blood borne viruses, its experience in developing and evaluating methods of virus inactivation applicable to purified protein derivatives, and because of the availability of our primate facility in Liberia. This project will further benefit from our supply of resource material; our laboratory, pilot plant, and components facilities; and our experience in handling and analyzing plasma proteins and blood components and in preparing experimental and licensed biologics for therapeutic use in humans.